Grunnleggende statistikk
| CIK | 1362959 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Rosetta Genomics, Ltd.
SEC Filings (Chronological Order)
På denne siden finner du en fullstendig, kronologisk liste over SEC-arkiveringer, med unntak av eierskaps-arkiveringer som vi leverer andre steder.
| May 18, 2018 |
Exhibit 99.1 Nasdaq Hearing Panel determined to delist shares of Rosetta Genomics from Nasdaq Stock Market effective May 22, 2018 PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / May 18, 2018 / Rosetta Genomics Ltd. (the “Company”) (NASDAQ: ROSG) announced today that on May 18, 2018, it received a decision letter from NASDAQ Stock Market (“Nasdaq”) following a hearing that was held on May 17, 2 |
|
| May 18, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Executi |
|
| May 1, 2018 |
ROSG / Rosetta Genomics, Ltd. NT 20-F NT 20-F 1 tv492689nt20f.htm NT 20-F OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 001-33042 CUSIP NUMBER NOTIFICATION OF LATE FILING M82183209 (Check one): ¨ Form 10-K ¨ Form N-SAR x Form 20-F ¨ Form N-CSR ¨ Form 11-K ¨ Form 10-Q ¨ For |
|
| April 27, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) 6-K 1 tv4921956k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Isra |
|
| April 26, 2018 |
Rosetta Genomics Announces Shareholder Approval of Merger with Genoptix Exhibit 99.1 Rosetta Genomics Announces Shareholder Approval of Merger with Genoptix PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / April 26, 2018 / Rosetta Genomics Ltd. (the “Company”) (NASDAQ: ROSG) today announced that its shareholders approved a proposed merger with a subsidiary of Genoptix, Inc. (“Genoptix”) at an extraordinary general meeting of shareholders. The completion of the merg |
|
| April 26, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Execu |
|
| April 19, 2018 |
AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER EX-99.1 2 tv491442ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 2, dated as of April 17, 2018 (“Amendment No. 2”), to the Agreement and Plan of Merger, dated as of February 27, 2018 (as amended, the “Agreement”), by and among Genoptix, Inc., a Delaware corporation (“Parent”), Stone Marger Sub, Ltd., a company incorporated under the Laws of |
|
| April 19, 2018 |
AMENDMENT NO. 2 TO EXPENSE REIMBURSEMENT WAIVER AGREEMENT Exhibit 99.2 AMENDMENT NO. 2 TO EXPENSE REIMBURSEMENT WAIVER AGREEMENT This AMENDMENT NO. 2, dated as of April 17, 2018 (“Amendment No. 2”), to the Expense Reimbursement Waiver Agreement (as amended, the “Agreement”), dated as of February 27, 2018, by and between Rosetta Genomics Ltd., an Israeli corporation with a principal place of business at 10 Plaut Street, Science Park, Rehovot 76706, Israel |
|
| April 19, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) 6-K 1 tv4914426k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Isra |
|
| April 19, 2018 |
AMENDMENT NUMBER THREE TO LOAN AND SECURITY AGREEMENT Exhibit 99.3 AMENDMENT NUMBER THREE TO LOAN AND SECURITY AGREEMENT This AMENDMENT NUMBER THREE TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of April 17, 2018 by and among ROSETTA GENOMICS INC., a Delaware corporation (“Borrower”), ROSETTA GENOMICS LTD., a company incorporated under the Laws of the State of Israel (“Rosetta” and, together with Borrower, each a “Guarantor” an |
|
| April 19, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) 6-K 1 tv4914456k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Isra |
|
| April 17, 2018 |
Exhibit 99.1 Shareholder Meeting Adjourned to April 26, 2018 Rosetta Genomics Urges Shareholders to Vote FOR the Proposed Merger with Genoptix If shareholders do not approve the merger, outstanding ordinary shares likely will cease to have any value PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / April 17, 2018 / Rosetta Genomics Ltd. (the “Company”) (NASDAQ: ROSG) today announced that the ext |
|
| April 17, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Execu |
|
| April 10, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Execu |
|
| April 10, 2018 |
EX-99.1 2 tv490759ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ACTION REQUIRED BEFORE POTENTIAL BANKRUPTCY If shareholders do not approve the merger, outstanding ordinary shares likely will cease to have any value Price per ordinary share increased to an estimated $0.42 – $0.50 This is a new shareholder meeting and all shareholders of record as of March 20, 2018 need to vote again regardless of whether th |
|
| April 10, 2018 |
ROSG / Rosetta Genomics, Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Execu |
|
| April 5, 2018 |
Exhibit 99.1 Rosetta Genomics Urges Shareholders to Vote FOR the Proposed Merger with Genoptix If shareholders do not approve the merger, outstanding ordinary shares likely will cease to have any value This is a new shareholder meeting and all shareholders of record as of March 20, 2018 need to vote again regardless of whether they voted at the previous extraordinary meeting of shareholders held i |
|
| April 5, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Execu |
|
| March 13, 2018 |
Exhibit 99.1 ROSETTA GENOMICS LTD. 10 Plaut St., Rabin Science Park Rehovot, 76706 Israel Phone number +972-73-222-0700 Shareholders of Rosetta Genomics Ltd. (the “Company”), an Israeli corporation, are hereby invited to the Extraordinary General Meeting (the “Extraordinary Meeting”) of the shareholders of Rosetta Genomics Ltd. that will be held at 25901 Commercentre Dr., Lake Forest, CA 92630, on |
|
| March 13, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) 6-K 1 tv4880336k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Isra |
|
| March 13, 2018 |
AMENDMENT NO. 1 TO EXPENSE REIMBURSEMENT WAIVER AGREEMENT EX-99.8 9 tv488033ex99-8.htm EXHIBIT 99.8 Exhibit 99.8 AMENDMENT NO. 1 TO EXPENSE REIMBURSEMENT WAIVER AGREEMENT This AMENDMENT NO. 1, dated as of March 11, 2018 (“Amendment No. 1”), to the Expense Reimbursement Waiver Agreement (the “Agreement”), dated as of February 27, 2018, by and between Rosetta Genomics Ltd., an Israeli corporation with a principal place of business at 10 Plaut Street, Scien |
|
| March 13, 2018 |
EXPENSE REIMBURSEMENT WAIVER AGREEMENT Exhibit 99.7 EXPENSE REIMBURSEMENT WAIVER AGREEMENT This EXPENSE REIMBURSEMENT WAIVER AGREEMENT (this “Agreement”) is made and entered into as of February 27, 2018, by and between Genoptix, Inc., a Delaware corporation (“Parent”), and Rosetta Genomics Ltd. (the “Company”). RECITALS WHEREAS, the Agreement and Plan of Merger, by and among Parent, Parent on behalf of Stone Merger Sub, Ltd. (or any ot |
|
| March 13, 2018 |
AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER EX-99.4 5 tv488033ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 1, dated as of March 11, 2018 (“Amendment No. 1”), to the Agreement and Plan of Merger, dated as of February 27, 2018 (the “Agreement”), by and among Genoptix, Inc., a Delaware corporation (“Parent”), Stone Marger Sub, Ltd., a company incorporated under the Laws of the State of |
|
| March 13, 2018 |
AMENDMENT NUMBER ONE TO LOAN AND SECURITY AGREEMENT Exhibit 99.5 EXECUTION VERSION AMENDMENT NUMBER ONE TO LOAN AND SECURITY AGREEMENT This AMENDMENT NUMBER ONE TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of February 27, 2018 by and among ROSETTA GENOMICS INC., a Delaware corporation (the “Borrower”), ROSETTA GENOMICS LTD., a company incorporated under the Laws of the State of Israel (“Rosetta”), MINUET DIAGNOSTICS, INC., a |
|
| March 13, 2018 |
AMENDMENT NUMBER TWO TO LOAN AND SECURITY AGREEMENT Exhibit 99.6 AMENDMENT NUMBER TWO TO LOAN AND SECURITY AGREEMENT This AMENDMENT NUMBER TWO TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of March 11, 2018 by and among ROSETTA GENOMICS INC., a Delaware corporation (the “Borrower”), ROSETTA GENOMICS LTD., a company incorporated under the Laws of the State of Israel (“Rosetta” and, together with Borrower, each a “Guarantor” an |
|
| March 13, 2018 |
Exhibit 99.2 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLY E35155-S66559 This proxy, when properly executed, will be voted in the manner directed herein by the undersigned. If no direction is |
|
| March 13, 2018 |
Exhibit 99.3 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among: Genoptix, Inc., Stone MArger Sub Ltd., and ROSETTA GENOMICS LTD. Dated as of February 27, 2018 Table of Contents Page Article 1 THE MERGER 3 1.1 The Merger 3 1.2 Effective Time 3 1.3 The Closing 3 1.4 Effects of the Merger 3 1.5 Closing Purchase Price 4 1.6 Conversion of Company Shares 4 1.7 Company Equity Awards 5 1.8 Termi |
|
| March 12, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Execu |
|
| March 12, 2018 |
Exhibit 99.1 ROSETTA GENOMICS LTD. 10 Plaut St., Rabin Science Park Rehovot, 76706 Israel Phone number +972-73-222-0700 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held on April 17, 2018 Notice is hereby given that an Extraordinary General Meeting (the “Extraordinary Meeting”) of the shareholders of Rosetta Genomics Ltd. (the “Company”), an Israeli corporation, will be held at 25 |
|
| March 6, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Execu |
|
| March 6, 2018 |
Exhibit 99.1 Genoptix Completes Acquisition of PersonalizeDx from Rosetta Genomics First step in the process of Genoptix acquiring all of Rosetta Genomics Next step is the completion of a merger for $8 million in cash pursuant to which value to Rosetta Genomics’ equity holders is preliminarily estimated to be $0.40 - $0.45 per ordinary share, after deductions for debt, warrant termination payments |
|
| February 27, 2018 |
EX-99.1 2 tv487232ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ROSETTA GENOMICS LTD. 10 Plaut St., Rabin Science Park Rehovot, 76706 Israel Phone number +972-73-222-0700 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held on April 6, 2018 Notice is hereby given that an Extraordinary General Meeting (the “Extraordinary Meeting”) of the shareholders of Rosetta Genomics Ltd. (the “Company”), a |
|
| February 27, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| February 23, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| February 23, 2018 |
Exhibit 99.1 Rosetta Genomics Announces Results from Extraordinary General Meeting of Shareholders to Vote on Proposed Merger with Genoptix ? Although shares voted were more than 2-to-1 in favor of the merger, the proposal failed to secure a majority of shares outstanding ? Company considering alternative options with Genoptix LAKE FOREST, Calif., PHILADELPHIA and REHOVOT, Israel (February 23, 201 |
|
| February 16, 2018 |
Rosetta Genomics Urges Shareholders to Vote FOR the Proposed Merger with Genoptix EX-99.1 2 tv486391ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rosetta Genomics Urges Shareholders to Vote FOR the Proposed Merger with Genoptix · Shares voted to date are running 3-to-1 in favor of the merger · Emphasizes that shareholders as of December 27, 2017, regardless of whether or not they still hold their shares, are entitled to vote · This shareholders meeting cannot be adjourned any further CA |
|
| February 16, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| February 15, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| February 1, 2018 |
EX-99.1 2 tv484630ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IMPORTANT NOTICE FOR SHAREHOLDERS OF: ROSETTA GENOMICS LTD. PLEASE VOTE NOW AND HELP US AVOID FURTHER ADJOURNMENTS! February 1, 2018 Dear Fellow Shareholder, At the extraordinary meeting of shareholders held on February 1, 2018, we adjourned the meeting with respect to the proposal set forth and recommended by the Board of Directors of Rosetta |
|
| February 1, 2018 |
ROSG / Rosetta Genomics, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| January 22, 2018 |
EX-99.1 2 tv483676ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 January 22, 2018 Dear Fellow Shareholder, We are urgently seeking your proxy vote FOR approval of the proposed merger of Rosetta Genomics Ltd. (“Rosetta Genomics”) with a subsidiary of Genoptix, Inc. (the “Merger”). Under the terms of the Merger, Rosetta Genomics shareholders will be paid an amount preliminarily estimated to be $0.60 to $0.70 |
|
| January 22, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Exe |
|
| December 28, 2017 |
EX-99.1 2 tv482171ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ROSETTA GENOMICS LTD. 10 Plaut St., Rabin Science Park Rehovot, 76706 Israel Phone number +972-73-222-0700 Shareholders of Rosetta Genomics Ltd. (the “Company”), an Israeli corporation, are hereby invited to the Extraordinary General Meeting (the “Extraordinary Meeting”) of the shareholders of Rosetta Genomics Ltd. that will be held at the Cal |
|
| December 28, 2017 |
Exhibit 99.2 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLY E35155-S66559 This proxy, when properly executed, will be voted in the manner directed herein by the undersigned. If no direction is |
|
| December 28, 2017 |
6-K 1 tv482171-6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of December 2017 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Isr |
|
| December 27, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| December 22, 2017 |
Exhibit 99.1 ROSETTA GENOMICS LTD. 10 Plaut St., Rabin Science Park Rehovot, 76706 Israel Phone number +972-73-222-0700 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held on February 1, 2018 Notice is hereby given that an Extraordinary General Meeting (the “Extraordinary Meeting”) of the shareholders of Rosetta Genomics Ltd. (the “Company”), an Israeli corporation, will be held at |
|
| December 22, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| December 21, 2017 |
Exhibit 99.1 AGREEMENT AND PLAN OF MERGER by and among: Genoptix, Inc., Stone Merger Sub Ltd., and ROSETTA GENOMICS LTD. Dated as of December 14, 2017 Table of Contents Page Article 1 THE MERGER 2 1.1 The Merger 2 1.2 Effective Time 3 1.3 The Closing 3 1.4 Effects of the Merger 3 1.5 Closing Purchase Price 3 1.6 Conversion of Company Shares 4 1.7 Company Equity Awards 4 1.8 Termination of Company |
|
| December 21, 2017 |
Exhibit 99.3 Genoptix to Acquire Rosetta Genomics for $10 Million in Cash The value to Rosetta Genomics’ equity holders is preliminarily estimated to be $0.60 per ordinary share, after deductions for debt, warrant termination payments, fees, expenses and other items CARLSBAD, Calif., PHILADELPHIA and REHOVOT, Israel (December 15, 2017) – Genoptix, Inc., a leading oncology diagnostic laboratory, an |
|
| December 21, 2017 |
Exhibit 99.2 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”), dated as of December 14, 2017, is made by and among ROSETTA GENOMICS INC., a Delaware corporation (the “Borrower”), ROSETTA GENOMICS, LTD., a company incorporated under the Laws of the State of Israel (“Rosetta”), MINUET DIAGNOSTICS, INC., a Delaware corporation (“Minuet”), and CYNOGEN INC., a Delaware co |
|
| December 21, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| December 13, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of December 2017 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execu |
|
| December 6, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| November 30, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| November 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| October 30, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2017 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Exe |
|
| October 26, 2017 |
Exhibit 99.1 ROSETTA GENOMICS LTD. 10 Plaut St., Rabin Science Park Rehovot, 7670609 Israel Phone number +972-73-222-0700 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held On December 6, 2017 Notice is hereby given that an Annual General Meeting (the “Annual Meeting”) of the shareholders of Rosetta Genomics Ltd. (the “Company”), an Israeli corporation, will be held at the Philadelphia of |
|
| October 26, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of October 2017 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execut |
|
| October 25, 2017 |
ROSETTA GENOMICS LTD. October 25, 2017 ROSETTA GENOMICS LTD. October 25, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Irene Paik Re: Rosetta Genomics Ltd. (the “Company”) Registration Statement on Form F-1 (the “Registration Statement”) Filed October 16, 2017 File No. 333-220985 Dear Madam: Pursuant to Rule 461 under the Securities Act of 1933 |
|
| October 16, 2017 |
Amended and Restated Articles of Association. Exhibit 3.1 AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF ROSETTA GENOMICS LTD. A COMPANY LIMITED BY SHARES PRELIMINARY 1. COMPANY NAME The name of the company is “Rosetta Genomics Ltd.” (the “Company”). 2. INTERPRETATION (a) In these Articles, the following terms shall bear the meanings set forth below, unless inconsistent with the subject or context. “Office Holder” shall mean every director a |
|
| October 16, 2017 |
As filed with the Securities and Exchange Commission on October 16, 2017 As filed with the Securities and Exchange Commission on October 16, 2017 Registration No. |
|
| October 11, 2017 |
Form of Subsidiary Guaranttee, dated October 2, 2017, in the 2017 Private Placement Exhibit 10.3 SUBSIDIARY GUARANTEE SUBSIDIARY GUARANTEE, dated as of October 2, 2017 (this “Guarantee”), made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the “Guarantors”), in favor of the purchasers signatory (together with their permitted assigns, the “Purchasers”) to that certain Securities Purchase Agreement, dated as of t |
|
| October 11, 2017 |
Form of Placement Agent Warrant issued in the 2017 Private Placement Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| October 11, 2017 |
Form Ordinary Share Purchase Warrant issued in the 2017 Private Placement Exhibit 10.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| October 11, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2017 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Exe |
|
| October 11, 2017 |
Rosetta Genomics Announces $2 Million Private Placement Exhibit 99.1 Rosetta Genomics Announces $2 Million Private Placement PHILADELPHIA and REHOVOT, Israel (September 28, 2017) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, today announced it has entered into definitive agreements with one prominent institutional healthcare |
|
| October 11, 2017 |
Exhibit 10.5 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 28, 2017, between Rosetta Genomics Ltd., an Israeli corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| October 11, 2017 |
Exhibit 10.6 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of September , 2017, between Rosetta Genomics Ltd., an Israeli corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchas |
|
| October 11, 2017 |
Form of Debenture issued in the 2017 Private Placement Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| October 10, 2017 |
Exhibit 99.1 ROSETTA GENOMICS LTD. AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2016 U.S. DOLLARS IN THOUSANDS INDEX Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets F-3 - F-4 Consolidated Statements of Comprehensive Loss F-5 Consolidated Statements of Changes in Shareholders’ Equity F-6 Consolidated Statements of Cash Flows F-7 |
|
| October 10, 2017 |
Exhibit 99.1 ROSETTA GENOMICS LTD. AND ITS SUBSIDIARIES CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2017 UNAUDITED INDEX Page Condensed Interim Consolidated Balance Sheets 2 - 3 Condensed Interim Consolidated Statements of Comprehensive Loss 4 Condensed Interim Consolidated Statements of Changes in Shareholders’ Equity 5 Condensed Interim Consolidated Statements of Cash Flow |
|
| October 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2017 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Exe |
|
| October 10, 2017 |
Rosetta Genomics Reports 2017 Second Quarter and Six Months Financial Results Exhibit 99.2 Rosetta Genomics Reports 2017 Second Quarter and Six Months Financial Results PHILADELPHIA and REHOVOT, Israel (October 10, 2017) – Rosetta Genomics Ltd. (NASDAQ: ROSG) (“Rosetta” or the “Company”), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces financial results for the three and six mon |
|
| October 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2017 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Exe |
|
| September 25, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of September 2017 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal exec |
|
| September 18, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of September 2017 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal exec |
|
| August 16, 2017 |
Form of Unregistered Warrant issued in the 2017 Public Offering Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 16, 2017 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 3, 2017, between Rosetta Genomics Ltd., an Israeli company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set f |
|
| August 16, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2017 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal executi |
|
| August 14, 2017 |
Exhibit 99.1 ROSETTA GENOMICS LTD. 10 Plaut St., Rabin Science Park Rehovot, 76706 Israel Phone number +972-73-222-0700 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held On September 18, 2017 Notice is hereby given that an Extraordinary General Meeting (the “Extraordinary Meeting”) of the shareholders of Rosetta Genomics Ltd. (the “Company”), an Israeli corporation, will be held a |
|
| August 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2017 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal executi |
|
| August 7, 2017 |
As filed with the Securities and Exchange Commission on August 7, 2017 As filed with the Securities and Exchange Commission on August 7, 2017 Registration No. |
|
| August 7, 2017 |
Filed pursuant to Rule 424(b)(4) Registration No. 333-217765 PROSPECTUS 138,000 Class A Units consisting of Ordinary Shares and Series A Warrants and 1,811,974 Class B Units consisting of Pre-Funded Series B Warrants and Series A Warrants (2,786,961 Ordinary Shares underlying the Series A and Pre-Funded Series B Warrants) ROSETTA GENOMICS LTD. We are offering, on a best efforts basis, 138,000 Clas |
|
| August 2, 2017 |
ROSETTA GENOMICS LTD. August 2, 2017 ROSETTA GENOMICS LTD. August 2, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ada D. Sarmento Re: Rosetta Genomics Ltd. (the “Company”) Registration Statement on Form F-1 (the “Registration Statement”) Filed May 8, 2017, as Amended May 15, 2017, May 17, 2017, July 25, 2017 and August 2, 2017 File No. 333-21776 |
|
| August 2, 2017 |
Form of Series A Warrant issued in the 2017 Public Offering Exhibit 4.1 SERIES A WARRANT TO PURCHASE ORDINARY SHARES ROSETTA GENOMICS LTD. Warrant Shares: Issue Date: , 2017 THIS SERIES A WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof ( |
|
| August 2, 2017 |
As filed with the Securities and Exchange Commission on August 2, 2017 As filed with the Securities and Exchange Commission on August 2, 2017 Registration No. |
|
| August 2, 2017 |
Exhibit 10.17 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August [, 2017, between Rosetta Genomics Ltd., an Israeli company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set |
|
| August 2, 2017 |
August 2, 2017 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: ROSETTA GENOMICS LTD. Registration Statement on Form F-1 (Registration No. 333-217765) Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by Rosetta G |
|
| August 2, 2017 |
Form of Placement Agent Warrant issued in the 2017 Public Offering Exhibit 4.3 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES ROSETTA GENOMICS LTD. Warrant Shares: Issue Date: , 2017 THIS WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th |
|
| July 28, 2017 |
As filed with the Securities and Exchange Commission on July 28, 2017 As filed with the Securities and Exchange Commission on July 28, 2017 Registration No. |
|
| July 28, 2017 |
Exhibit 10.17 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July [, 2017, between Rosetta Genomics Ltd., an Israeli company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fo |
|
| July 26, 2017 |
As filed with the Securities and Exchange Commission on July 26, 2017 As filed with the Securities and Exchange Commission on July 26, 2017 Registration No. |
|
| July 25, 2017 |
July 26, 2017 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: ROSETTA GENOMICS LTD. Registration Statement on Form F-1 (Registration No. 333-217765) Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by Rosetta Ge |
|
| July 25, 2017 |
ROSETTA GENOMICS LTD. July 26, 2017 ROSETTA GENOMICS LTD. July 26, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ada D. Sarmento Re: Rosetta Genomics Ltd. (the “Company”) Registration Statement on Form F-1 (the “Registration Statement”) Filed May 8, 2017, as Amended May 15, 2017, May 17, 2017 and July 25, 2017 File No. 333-217765 Dear Ms. Sarmen |
|
| May 17, 2017 |
As filed with the Securities and Exchange Commission on May 17, 2017 F-1/A 1 v467247f1a.htm F-1/A As filed with the Securities and Exchange Commission on May 17, 2017 Registration No. 333-217765 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Amendment No. 2 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ROSETTA GENOMICS LTD. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’ |
|
| May 17, 2017 |
SERIES A WARRANT TO PURCHASE ORDINARY SHARES ROSETTA GENOMICS LTD. Exhibit 4.1 SERIES A WARRANT TO PURCHASE ORDINARY SHARES ROSETTA GENOMICS LTD. Warrant Shares: Issue Date: , 2017 THIS SERIES A WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exerc |
|
| May 17, 2017 |
PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES ROSETTA GENOMICS LTD. Exhibit 4.3 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES ROSETTA GENOMICS LTD. Warrant Shares: Issue Date: , 2017 THIS WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercis |
|
| May 17, 2017 |
Exhibit 10.17 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May , 2017, between Rosetta Genomics Ltd., an Israeli company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fort |
|
| May 17, 2017 |
May 17, 2017 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: ROSETTA GENOMICS LTD. Registration Statement on Form F-1 (Registration No. 333-217765) Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by Rosetta Gen |
|
| May 17, 2017 |
ROSETTA GENOMICS LTD. May 17, 2017 ROSETTA GENOMICS LTD. May 17, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ada D. Sarmento Re: Rosetta Genomics Ltd. (the “Company”) Registration Statement on Form F-1 (the “Registration Statement”) Filed May 8, 2017, as Amended May 15, 2017 and May 17, 2017 File No. 333-217765 Dear Ms. Sarmento: Pursuant to |
|
| May 17, 2017 |
Exhibit 1.1 April 21, 2017 STRICTLY CONFIDENTIAL Rosetta Genomics Ltd. 10 Plaut Street, Science Park Rehovot 76706, Israel Attn: Kenneth A. Berlin, Chief Executive Officer Dear Mr. Berlin: This letter agreement (this “Agreement”) constitutes the agreement between Rosetta Genomics Ltd. (the “Company”) and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (“Rodman”), that Rodman shall serve as |
|
| May 17, 2017 |
Form Pre-Funded Series B Warrant issued in the 2017 Public Offering Exhibit 4.2 SERIES B PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES ROSETTA GENOMICS LTD. Warrant Shares: Issue Date: , 2017 THIS SERIES B PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a |
|
| May 15, 2017 |
As filed with the Securities and Exchange Commission on May 15, 2017 As filed with the Securities and Exchange Commission on May 15, 2017 Registration No. |
|
| May 15, 2017 |
ROSETTA GENOMICS LTD. May 8, 2017 EXHIBIT 10.18 ROSETTA GENOMICS LTD. WAIVER May 8, 2017 This Waiver is made by and among Rosetta Genomics Ltd, an Israeli corporation (the “Company”), and each Purchaser that is a party to (i) that certain Securities Purchase Agreement, dated November 23, 2016, by and between the Company and each such Purchaser (the “Purchase Agreement”) and (ii) that certain Registration Rights Agreement, dated No |
|
| May 8, 2017 |
As filed with the Securities and Exchange Commission on May 8, 2017 As filed with the Securities and Exchange Commission on May 8, 2017 Registration No. |
|
| April 25, 2017 |
As filed with the Securities and Exchange Commission on April 25, 2017 As filed with the Securities and Exchange Commission on April 25, 2017 Registration No. |
|
| April 4, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2017 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Execu |
|
| March 30, 2017 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-163063, 333-171203, 333-172655, 333-177670, 333-185338, 333-207697, and 333-210366) and Form S-8 (Nos. 333-141525, 333-147805, 333-165722 and 333-191072) pertaining to the Rosetta Genomics Ltd. Global Share Incentive Plan (2006), as |
|
| March 30, 2017 |
Exhibit 12.2 CERTIFICATIONS I, Ron Kalfus, certify that: 1. I have reviewed this Annual Report on Form 20-F of Rosetta Genomics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to |
|
| March 30, 2017 |
CERTIFICATIONS UNDER SECTION 906 Exhibit 13.1 CERTIFICATIONS UNDER SECTION 906 Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Rosetta Genomics Ltd., an Israeli corporation (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report on Form 20-F for the year ended Dece |
|
| March 30, 2017 |
Exhibit 12.1 CERTIFICATIONS I, Kenneth A. Berlin, certify that: 1. I have reviewed this Annual Report on Form 20-F of Rosetta Genomics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with res |
|
| March 30, 2017 |
As filed with the Securities and Exchange Commission on March 30, 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 16, 2017 |
Exhibit 99.1 ROSETTA GENOMICS ANNounces 1-for-12 reverse stock split Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on March 17, 2017 PHILADELPHIA and REHOVOT, Israel (March 16, 2017) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces the effectiveness |
|
| March 16, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Execu |
|
| March 16, 2017 |
AMENDED AND RESTATED ARTICLES OF ASSOCIATION ROSETTA GENOMICS LTD. A COMPANY LIMITED BY SHARES Exhibit 1.1 AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF ROSETTA GENOMICS LTD. A COMPANY LIMITED BY SHARES PRELIMINARY 1. COMPANY NAME The name of the company is “Rosetta Genomics Ltd.” (the “Company”). 2. INTERPRETATION (a) In these Articles, the following terms shall bear the meanings set forth below, unless inconsistent with the subject or context. “Office Holder” shall mean every director a |
|
| March 13, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Execu |
|
| February 23, 2017 |
Rosetta Genomics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of February 2017 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execu |
|
| February 23, 2017 |
Exhibit 99.1 February 23, 2017 Rosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible Debentures PHILADELPHIA and REHOVOT, Israel (February 23, 2017) ? Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces the closing of the secon |
|
| February 16, 2017 |
5,170,000 Ordinary Shares ROSETTA GENOMICS LTD. Filed pursuant to the Rule 424(b)(3) Registration No. 333-214981 5,170,000 Ordinary Shares ROSETTA GENOMICS LTD. This prospectus relates to the resale, from time to time, by the selling stockholders named in this prospectus or their pledgees, donees, transferees, or other successors in interest of up to 5,170,000 of our ordinary shares issuable upon conversion of convertible debentures (the ?PIPE |
|
| February 15, 2017 |
Rosetta Genomics 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of February 2017 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execu |
|
| February 14, 2017 |
As filed with the Securities and Exchange Commission on February 14, 2017 Registration No. |
|
| February 14, 2017 |
Rosetta Genomics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of February 2017 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execu |
|
| February 14, 2017 |
ROSETTA GENOMICS LTD. February 14, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Joseph McCann Re: Rosetta Genomics Ltd. (the “Company”) Registration Statement on Form F-1 (the “Registration Statement”) Filed December 8, 2016 File No. 333-214981 Dear Mr. McCann: We are hereby filing with the Securities and Exc |
|
| February 3, 2017 |
Exhibit 99.1 ROSETTA GENOMICS LTD. 10 Plaut St., Rabin Science Park Rehovot, 76706 Israel Phone number +972-73-222-0700 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held On March 16, 2017 Notice is hereby given that an Extraordinary General Meeting (the ?Extraordinary Meeting?) of the shareholders of Rosetta Genomics Ltd. (the ?Company?), an Israeli corporation, will be held at th |
|
| February 3, 2017 |
Rosetta Genomics 6-K (Current Report of Foreign Issuer) 6-K 1 v4583486k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of February 2017 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Ad |
|
| January 27, 2017 |
Brian P. Keane | 617 348 3093 | [email protected] One Financial Center Boston, MA 02111 617-542-6000 617-542-2241 fax www.mintz.com January 27, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes Joseph McCann Re: Rosetta Genomics Ltd. Registration Statement on Form F-1 Response dated January 10, 2017 F |
|
| January 25, 2017 |
Rosetta Genomics FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4575416k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of January 2017 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel |
|
| January 10, 2017 |
Brian P. Keane | 617 348 3093 | [email protected] One Financial Center Boston, MA 02111 617-542-6000 617-542-2241 fax www.mintz.com January 10, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes Joseph McCann Re: Rosetta Genomics Ltd. Registration Statement on Form F-1 Filed December 8, 2016 File No. 3 |
|
| December 20, 2016 |
EXHIBIT 99.1 Rosetta Genomics Reports Third Quarter 2016 Financial Results Introduces 2017 Revenue and Unit Guidance for RosettaGX Reveal PHILADELPHIA and REHOVOT, Israel (December 20, 2016) ? Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces financial results for th |
|
| December 20, 2016 |
Rosetta Genomics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of December 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execu |
|
| December 8, 2016 |
As filed with the Securities and Exchange Commission on December 8, 2016 Registration No. |
|
| December 8, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of December 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execu |
|
| December 8, 2016 |
EXHIBIT 99.1 ROSETTA GENOMICS LTD. AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2015 U.S. DOLLARS IN THOUSANDS INDEX Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets F-3 - F-4 Consolidated Statements of Comprehensive Loss F-5 Consolidated Statements of Changes in Shareholders' Equity F-6 Consolidated Statements of Cash Flows F-7 |
|
| December 8, 2016 |
Consent of Independent Registered Public Accounting Firm EXHIBIT 99.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-163063, 333-171203, 333-172655, 333-177670, 333-185338, 333-207697 and 333-210366) and the related prospectuses and Form S-8 (Nos. 333-141525, 333-147805, 333-165722 and 333-191072) of Rosetta Genomics Ltd. of our report dated March |
|
| November 28, 2016 |
1,095,000 ORDINARY SHARES $3,160,000 CONVERTIBLE DEBENTURES Filed pursuant to Rule 424(b)(5) Registration File No. 333-210366 PROSPECTUS SUPPLEMENT To prospectus dated March 30, 2016 1,095,000 ORDINARY SHARES $3,160,000 CONVERTIBLE DEBENTURES We are offering 1,095,000 ordinary shares, NIS 0.6 par value per share, at a price of $0.50 per share, and $3,160,000 in principal amount of convertible debentures (hereinafter referred to as the Registered Debentures |
|
| November 25, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execu |
|
| November 25, 2016 |
Form of 2016 Warrant issued to investors in the 2016 Offerings. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 25, 2016 |
Form of Placement Agent Warrant issued to the Placement Agents and affiliates in the 2016 Offerings. EX-4.5 7 v453901ex4-5.htm EXHIBIT 4.5 Exhibit 4.5 NEITHER THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A RE |
|
| November 25, 2016 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of November , 2016, between Rosetta Genomics Ltd., an Israeli corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase |
|
| November 25, 2016 |
EX-1.1 2 v453901ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 CO-PLACEMENT AGENCY AGREEMENT November 23, 2016 Aegis Capital Corp. 810 Seventh Avenue, 18th Floor New York, NY 10019 Maxim Group LLC 405 Lexington Avenue New York, New York 10174 Ladies and Gentlemen: Rosetta Genomics Ltd, an Israeli corporation (the “Company”), proposes, subject to the terms and conditions herein, to issue and sell an aggregate o |
|
| November 25, 2016 |
Subsidiary Guarantee, dated November 29, 2016, issued to investors in the 2016 Offerings. Exhibit 4.4 SUBSIDIARY GUARANTEE SUBSIDIARY GUARANTEE, dated as of November , 2016 (this “Guarantee”), made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the “Guarantors”), in favor of the purchasers signatory (together with their permitted assigns, the “Purchasers”) to that certain Securities Purchase Agreement, dated as of th |
|
| November 25, 2016 |
Exhibit 99.1 Rosetta Genomics Announces Pricing of $5 Million Concurrent Registered Direct and Private Placement Offering PHILADELPHIA and REHOVOT, Israel (November 23, 2016) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, today announced it has entered into definitive agreements with one prominent institut |
|
| November 25, 2016 |
Form of PIPE Debenture issued to investors in the 2016 Offerings. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| November 25, 2016 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 23, 2016, between Rosetta Genomics Ltd., an Israeli corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| November 25, 2016 |
Form of Registered Debenture issued to investors in the 2016 Offerings. Exhibit 4.2 Original Issue Date: November 29, 2016 Original Conversion Price (subject to adjustment herein): $0.50 $ CONVERTIBLE DEBENTURE DUE November 29, 2046 THIS CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued Convertible Debentures of Rosetta Genomics Ltd., an Israeli corporation, (the “Company”), having its principal place of business at 10 Plaut street, Scienc |
|
| October 20, 2016 |
Rosetta Genomics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of October 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execut |
|
| October 20, 2016 |
Exhibit 99.1 News Release Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer Brings extensive molecular diagnostic commercial and market access leadership to drive revenue and expand reimbursement across portfolio of high-value assays Company expects to build on momentum of RosettaGX Reveal? gross billings which demonstrated over 60% volume growth from August to September PHILADE |
|
| October 14, 2016 |
Rosetta Genomics FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4506126k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of October 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel |
|
| October 13, 2016 |
Rosetta Genomics 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of October 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execut |
|
| September 26, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of September 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal exec |
|
| September 26, 2016 |
EX-99.2 3 v449131ex99-2.htm EXHIBIT 99.2 News Release Rosetta Genomics Reports 2016 Second Quarter Financial Results RosettaGX Reveal for the Diagnosis of Indeterminate Thyroid FNA Expected to Drive Significant Revenue Growth over the Next Several Years Conference call begins today at 4:30 p.m. Eastern time PHILADELPHIA and REHOVOT, Israel (September 26, 2016) – Rosetta Genomics Ltd. (NASDAQ: ROSG |
|
| September 26, 2016 |
Exhibit 99.1 ROSETTA GENOMICS LTD. AND ITS SUBSIDIARIES CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2016 UNAUDITED INDEX Page Condensed Interim Consolidated Balance Sheets 2 - 3 Condensed Interim Consolidated Statements of Comprehensive Loss 4 Condensed Interim Consolidated Statements of Changes in Shareholders' Equity 5 Condensed Interim Consolidated Statements of Cash Flow |
|
| August 22, 2016 |
Rosetta Genomics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal executi |
|
| August 22, 2016 |
Rosetta Genomics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal executi |
|
| August 8, 2016 |
Rosetta Genomics 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal executi |
|
| August 1, 2016 |
Rosetta Genomics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal executi |
|
| June 24, 2016 |
Rosetta Genomics 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of June 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal executive |
|
| June 24, 2016 |
Exhibit 99.1 ROSETTA GENOMICS LTD. 10 Plaut St., Rabin Science Park Rehovot, 7670609 Israel Phone number +972-73-222-0700 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held On August 1, 2016 Notice is hereby given that an Annual General Meeting (the ?Annual Meeting?) of the shareholders of Rosetta Genomics Ltd. (the ?Company?), an Israeli corporation, will be held at the Philadelphia offi |
|
| June 21, 2016 |
Exhibit 99.1 News Release Rosetta Genomics Receives Approval from New York State for HEME FISH-based Assays Portfolio of Disease-Specific Diagnostic, Prognostic and Predictive Test Panels for Various Hematologic Malignancies Now Available in all 50 States PHILADELPHIA and REHOVOT, Israel (June 21, 2016) ? Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and |
|
| June 21, 2016 |
Rosetta Genomics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of June 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal executive |
|
| May 26, 2016 |
Rosetta Genomics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal executive |
|
| May 19, 2016 |
Rosetta Genomics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal executive |
|
| May 19, 2016 |
Exhibit 99.1 News Release Rosetta Genomics Reports 2016 First Quarter Financial Results Record Quarterly Clinical Testing Revenues of $2.6 million Conference call begins today at 10:00 a.m. Eastern time PHILADELPHIA and REHOVOT, Israel (May 19, 2016) ? Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial |
|
| March 30, 2016 |
$75,000,000 Ordinary Shares Debt Securities Rights Warrants Units Filed Pursuant to Rule 424(b)(2) Registration No. 333-210366 PROSPECTUS $75,000,000 Ordinary Shares Debt Securities Rights Warrants Units We may offer and sell from time to time in one or more offerings our ordinary shares, debt securities, rights, warrants and units comprising any combination of these securities having an aggregate offering price up to $75,000,000. Each time we sell securities pu |
|
| March 28, 2016 |
ROSETTA GENOMICS LTD. March 28, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dorrie Yale Re: Rosetta Genomics Ltd. Registration Statement on Form F-3 Filed March 23, 2016 File No. 333-210366 Dear Ms. Yale: With respect to the above-referenced Registration Statement on Form F-3 (the “Registration Statement”), |
|
| March 23, 2016 |
Exhibit 4.3 FORM OF SUBORDINATED DEBT SECURITIES INDENTURE ROSETTA GENOMICS LTD. INDENTURE DATED AS OF , 20 TRUSTEE SUBORDINATED DEBT SECURITIES Table of Contents Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 2 Section 1.1. Definitions 2 Section 1.2. Definitions 5 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. SECURITI |
|
| March 23, 2016 |
Exhibit 4.2 FORM OF SENIOR INDENTURE ROSETTA GENOMICS LTD. ISSUER and [ ], TRUSTEE INDENTURE Dated as of [ ], 200[] Senior Debt Securities CROSS-REFERENCE TABLE1 Section of Trust Indenture Act Section of of 1939, as amended Section of Indenture 310(a) 7.09 310(b) 7.08, 7.10 310(c) Inapplicable 311(a) 7.13 311(b) 7.13 311(c) Inapplicable 312(a) 5.01, 5.02(a) 312(b) 5.02(c) 312(c) 5.02(c) 313(a) 5.0 |
|
| March 23, 2016 |
As filed with the Securities and Exchange Commission on March 23, 2016 Registration No. |
|
| March 23, 2016 |
Exhibit 12.1 CERTIFICATIONS I, Kenneth A. Berlin, certify that: 1. I have reviewed this Annual Report on Form 20-F of Rosetta Genomics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with res |
|
| March 23, 2016 |
Exhibit 4.3 MADAI'IM 1 Contract of Lease Prepared and signed in Tel Aviv on in the month of December 2008 - BETWEEN - 1. Rorberg Developers and Investors (1963) Ltd. Private Registered Company Number 51 - 041126 - 7 2. Tazor Development Ltd. Private Registered Company Number 51 - 196 01 -1 Whose address for the purpose of this Contract with Rorberg Developers and Investors (1963) Ltd Of 9, Bonei H |
|
| March 23, 2016 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-163063, 333-171203, 333-172655, 333-177670, 333-185338 and 333-207697) and Form S-8 (Nos. 333-141525, 333-147805, 333-165722 and 333-191072) pertaining to the Rosetta Genomics Ltd. Global Share Incentive Plan (2006), as amended, of |
|
| March 23, 2016 |
EXHIBIT 4.14 STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of April 3, 2015, by and between Prelude Corporation, a Delaware corporation (“Seller”), and Rosetta Genomics Inc., a Delaware corporation (“Buyer,”) and Rosetta Genomics Ltd., an Israeli corporation ("Buyer Parent")(together with Buyer and Seller, the “Parties”). RECITALS WHEREAS, Se |
|
| March 23, 2016 |
v434506ex4-4 - Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing Exhibit 4.4 FIRST Amendment to air commercial real estate association standard industrial/commercial single-tenant lease -net This First Amendment to the AIR COMMERCIAL REAL ESTATE ASSOCIATION STANDARD INDUSTRIAL/COMMERCIAL SINGLE-TENANT LEASE - NET (this “Amendment”) is dated as of April 13, 2015 (t |
|
| March 23, 2016 |
Exhibit 12.2 CERTIFICATIONS I, Ron Kalfus, certify that: 1. I have reviewed this Annual Report on Form 20-F of Rosetta Genomics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to |
|
| March 23, 2016 |
AMENDED AND RESTATED ARTICLES OF ASSOCIATION ROSETTA GENOMICS LTD. A COMPANY LIMITED BY SHARES Exhibit 1.1 AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF ROSETTA GENOMICS LTD. A COMPANY LIMITED BY SHARES PRELIMINARY 1. COMPANY NAME The name of the company is “Rosetta Genomics Ltd.” (the “Company”). 2. INTERPRETATION (a) In these Articles, the following terms shall bear the meanings set forth below, unless inconsistent with the subject or context. “Office Holder” shall mean every director a |
|
| March 23, 2016 |
As filed with the Securities and Exchange Commission on March 23, 2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 23, 2016 |
CERTIFICATIONS UNDER SECTION 906 Exhibit 13.1 CERTIFICATIONS UNDER SECTION 906 Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Rosetta Genomics Ltd., an Israeli corporation (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report on Form 20-F for the year ended Dece |
|
| March 4, 2016 |
ROSG / Rosetta Genomics, Ltd. / DOLPHIN OFFSHORE PARTNERS LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Rosetta Genomics Ltd. (Name of Issuer) Ordinary Shares NIS $0.06 par value per share (Title of Class of Securities) M82183126 (CUSIP Number) Peter E. Salas P.O. Box 16867, Fernandina Beach, FL 32035 (904) 491-5003 (Name, Address and Telephone Number of Pe |
|
| February 25, 2016 |
Exhibit 99.1 News Release Rosetta Genomics Receives Approval from New York State for First-of-its-kind Thyroid Cancer Diagnostic Assay Conditional Approval makes RosettaGX Reveal? Available in all 50 States PHILADELPHIA and REHOVOT, Israel (February 18, 2016) ? Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, |
|
| February 25, 2016 |
Exhibit 99.2 News Release Rosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of Three New Product Offerings HEME FISH, BRAF Lung and NRAS Colon Assays Expand Oncology Franchise in Common Hematologic Cancers and Solid Tumors PHILADELPHIA and REHOVOT, Israel (February 25, 2016) ? Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other mole |
|
| February 25, 2016 |
Rosetta Genomics FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of February 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant?s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execu |
|
| January 19, 2016 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rosetta Genomics Ltd. (Name of Issuer) Ordinary Shares, NIS 0.6 par value (Title of Class of Securities) M82183126 (CUSIP Number) December 31, 2015 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 6, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of January 2016 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execut |
|
| January 6, 2016 |
Exhibit 99.1 News Release Rosetta Genomics Grants Sublicenses to Mirna Therapeutics for microRNA-related Patents for the Development of Oncology Therapeutics PHILADELPHIA, REHOVOT, Israel (January 6, 2016) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the signing of an agreement with Mirna Therapeutics (N |
|
| December 3, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of December 2015 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execu |
|
| December 3, 2015 |
ROSETTA GENOMICS LTD. AMENDMENT TO SERIES B WARRANT TO PURCHASE ORDINARY SHARES Exhibit 4.1 ROSETTA GENOMICS LTD. AMENDMENT TO SERIES B WARRANT TO PURCHASE ORDINARY SHARES This Amendment (this “Amendment”) to each Series B Warrant (each a “Series B Warrant,” and collectively the “Series B Warrants”) issued pursuant to that certain Securities Purchase Agreement, dated as of October 13, 2015, by and among Rosetta Genomics Ltd., a company organized under the laws of the State of |
|
| December 3, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2015 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| December 1, 2015 |
Rosetta Genomics Reports Third Quarter 2015 Financial Results Exhibit 99.1 News Release Rosetta Genomics Reports Third Quarter 2015 Financial Results PHILADELPHIA and REHOVOT, Israel (December 1, 2015) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the three and nine months ended September 30, 2015. Highlights for the third quarter of 2015 and re |
|
| December 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of December 2015 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execu |
|
| November 23, 2015 |
SC 13G 1 p15-2254sc13g.htm EMPERY ASSET MANAGEMENT, LP SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rosetta Genomics Ltd. (Name of Issuer) Ordinary Shares, NIS 0.6 par value (Title of Class of Securities) M82183126 (CUSIP Number) October 13, 2015 (Date of event which requires filing of this statement) Check the a |
|
| November 10, 2015 |
7,766,666 Ordinary Shares ROSETTA GENOMICS LTD. Filed Pursuant to Rule 424(b)(3) Registration No. 333-207697 7,766,666 Ordinary Shares ROSETTA GENOMICS LTD. This prospectus relates to the resale, from time to time, by the selling stockholders named in this prospectus or their pledgees, donees, transferees, or other successors in interest of up to 7,766,666 of our ordinary shares. These shares consist of (i) 3,333,333 issued and outstanding ordi |
|
| November 9, 2015 |
ROSETTA GENOMICS LTD. November 9, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Christina De Rosa Re: Rosetta Genomics Ltd. Registration Statement on Form F-3 Filed October 30, 2015 File No. 333-207697 Dear Ms. De Rosa: With respect to the above-referenced Registration Statement on Form F-3 (the “Registration |
|
| November 3, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2015 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| October 30, 2015 |
As filed with the Securities and Exchange Commission on October 30, 2015 As filed with the Securities and Exchange Commission on October 30, 2015 Registration No. |
|
| October 27, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of October 2015 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execut |
|
| October 27, 2015 |
EX-99.1 2 v422889ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ROSETTA GENOMICS LTD. 10 Plaut St., Rabin Science Park Rehovot, 7670609 Israel Phone number +972-73-222-0700 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held On December 3, 2015 Notice is hereby given that an Annual General Meeting (the “Annual Meeting”) of the shareholders of Rosetta Genomics Ltd. (the “Company”), an Israeli corpora |
|
| October 26, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of October 2015 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execut |
|
| October 26, 2015 |
EX-99.1 2 v422181ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ROSETTA GENOMICS LTD. AND ITS SUBSIDIARIES CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2015 UNAUDITED INDEX Page Condensed Interim Consolidated Balance Sheets 2 - 3 Condensed Interim Consolidated Statements of Loss 4 Condensed Interim Consolidated Statements of Changes in Shareholders' Equity 5 Condensed Interim Consolida |
|
| October 26, 2015 |
Exhibit 99.3 UNAUDITED COMBINED PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE SIX MONTH PERIOD ENDED JUNE 30, 2015 On April 9, 2015, Rosetta Genomics Inc. (“Rosetta” or the “Company“), a wholly-owned subsidiary of Rosetta Genomics, Ltd., entered into a Stock Purchase Agreement (the "SPA") pursuant to which it agreed to acquire CynoGen, Inc. (“CynoGen”) from Prelude Corporation, |
|
| October 26, 2015 |
Exhibit 99.2 INDEX TO FINANCIAL STATEMENTS Unaudited Condensed Financial Statements Condensed Statements of Operations F-2 Condensed Balance Sheets F-3 Condensed Statements of Cash Flows F-4 Notes to the Condensed Financial Statements F-5 F-1 CynoGen, Inc. Condensed Statements of Operations (Unaudited) (in thousands) Three Months Ended March 31 2015 2014 Net Sales $ 1,734 $ 889 Cost of services pr |
|
| October 14, 2015 |
Exhibit 4.2 ROSETTA GENOMICS LTD. SERIES B Warrant To Purchase Ordinary Shares (PARTIALLY PREPAID) Warrant No.: B-[] Number of Ordinary Shares: Determined in accordance with the formula set forth in the definition of Warrant Share Number. Date of Issuance: October , 2015 ("Issuance Date") Rosetta Genomics Ltd., a company organized under the laws of the State of Israel (the "Company"), hereby certi |
|
| October 14, 2015 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of October 13, 2015, between Rosetta Genomics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made |
|
| October 14, 2015 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of October 13, 2015, between Rosetta Genomics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made |
|
| October 14, 2015 |
ROSETTA GENOMICS LTD. SERIES B Warrant To Purchase Ordinary Shares (PARTIALLY PREPAID) Exhibit 4.2 ROSETTA GENOMICS LTD. SERIES B Warrant To Purchase Ordinary Shares (PARTIALLY PREPAID) Warrant No.: B-[] Number of Ordinary Shares: Determined in accordance with the formula set forth in the definition of Warrant Share Number. Date of Issuance: October , 2015 ("Issuance Date") Rosetta Genomics Ltd., a company organized under the laws of the State of Israel (the "Company"), hereby certi |
|
| October 14, 2015 |
ROSETTA GENOMICS LTD. SERIES A Warrant To Purchase Ordinary Shares Exhibit 4.1 ROSETTA GENOMICS LTD. SERIES A Warrant To Purchase Ordinary Shares Warrant No.: A-[] Number of Ordinary Shares: [] Date of Issuance: October , 2015 ("Issuance Date") Rosetta Genomics Ltd., a company organized under the laws of the State of Israel (the "Company"), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] |
|
| October 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A (Amendment to Report Filed October 14, 2015) Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of October 2015 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Reh |
|
| October 14, 2015 |
Exhibit 4.1 ROSETTA GENOMICS LTD. SERIES A Warrant To Purchase Ordinary Shares Warrant No.: A-[] Number of Ordinary Shares: [] Date of Issuance: October , 2015 ("Issuance Date") Rosetta Genomics Ltd., a company organized under the laws of the State of Israel (the "Company"), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] |
|
| October 14, 2015 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 13, 2015, between Rosetta Genomics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, |
|
| October 14, 2015 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 13, 2015, between Rosetta Genomics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, |
|
| October 14, 2015 |
Rosetta Genomics Raises $8,000,000 in Private Placement Exhibit 99.1 Rosetta Genomics Raises $8,000,000 in Private Placement October 14, 2015 PHILADELPHIA, PA. and REHOVOT, Israel (October 14, 2015) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced it has entered into definitive agreements with investors to purchase an aggregate of $8,000,000 in units, consisting |
|
| October 14, 2015 |
Rosetta Genomics Raises $8,000,000 in Private Placement Exhibit 99.1 Rosetta Genomics Raises $8,000,000 in Private Placement October 14, 2015 PHILADELPHIA, PA. and REHOVOT, Israel (October 14, 2015) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced it has entered into definitive agreements with investors to purchase an aggregate of $8,000,000 in units, consisting |
|
| October 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of October 2015 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execut |
|
| October 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2015 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal execut |
|
| September 28, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September, 2015 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal exe |
|
| September 21, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September, 2015 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal exe |
|
| July 8, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July, 2015 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal executiv |
|
| July 8, 2015 |
Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION AS OF DECEMBER 31, 2014 AND THE YEAR ENDED DECEMBER 31, 2014 Unaudited Pro Forma Financial Information On April 9, 2015, Rosetta Genomics Inc. (“Rosetta” or the “Company“), our wholly-owned subsidiary, entered into a Stock Purchase Agreement (the "SPA") pursuant to which it agreed to acquire CynoGen, Inc. from Prelude Corpor |
|
| July 8, 2015 |
Consent of Independent Auditors Exhibit 99.3 Consent of Independent Auditors We consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-163063, 333-171203, 333-172655, 333-177670 and 333-185338) and Form S-8 (Nos. 333-141525, 333-147805, 333-165722 and 333-191072) of Rosetta Genomics Ltd. of our report dated June 29, 2015, with respect to the financial statements of CynoGen, Inc. for the ye |
|
| July 8, 2015 |
Exhibit 99.2 INDEX TO FINANCIAL STATEMENTS Audited Financial Statements Independent Auditors’ Report F-2 Statements of Operations F-3 Balance Sheets F-4 Statements of Changes in Parent Company Investment in CynoGen F-5 Statements of Cash Flows F-6 Notes to the Financial Statements F-7 F-1 Report of Independent Auditors To The Management of Abbott Laboratories We have audited the accompanying finan |
|
| July 8, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July, 2015 Commission File Number 001-33042 Rosetta Genomics Ltd. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of principal executiv |
|
| July 8, 2015 |
Up to $3,600,000 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-185338 PROSPECTUS SUPPLEMENT (To Prospectus Dated December 19, 2012) Up to $3,600,000 Ordinary Shares We entered into a Controlled Equity Offering SM sales agreement, dated February 18, 2015, with Cantor Fitzgerald & Co. relating to our ordinary shares offered by this prospectus supplement and the accompanying prospectus. In accordance with the |
|
| April 14, 2015 |
Rosetta Genomics Completes Acquisition of PersonalizeDx Exhibit 99.2 News Release Rosetta Genomics Completes Acquisition of PersonalizeDx PRINCETON, N.J. and REHOVOT, Israel (April 14, 2015) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the closing of its acquisition of CynoGen, Inc. (d/b/a PersonalizeDx) from Prelude Corporation. “We are delighted to complete this |
|
| April 14, 2015 |
Rosetta Genomics to Acquire PersonalizeDx Exhibit 99.1 News Release Rosetta Genomics to Acquire PersonalizeDx · Creates a broader commercial footprint and expanded product offering in oncology diagnostics with numerous near-term product launches to accelerate revenue growth · Enhances Rosetta Genomics’ leadership as a provider of proprietary and differentiated content in the personalized medicine arena · Rosetta Genomics expects annualize |
|
| April 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2015 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Execu |
|
| March 16, 2015 |
AMENDED AND RESTATED ARTICLES OF ASSOCIATION ROSETTA GENOMICS LTD. A COMPANY LIMITED BY SHARES Exhibit 1.1 AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF ROSETTA GENOMICS LTD. A COMPANY LIMITED BY SHARES PRELIMINARY 1. COMPANY NAME The name of the company is “Rosetta Genomics Ltd.” (the “Company”). 2. INTERPRETATION (a) In these Articles, the following terms shall bear the meanings set forth below, unless inconsistent with the subject or context. “Office Holder” shall mean every director a |
|
| March 16, 2015 |
Exhibit 12.1 CERTIFICATIONS I, Kenneth A. Berlin, certify that: 1. I have reviewed this Annual Report on Form 20-F of Rosetta Genomics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with res |
|
| March 16, 2015 |
Exhibit 12.2 CERTIFICATIONS I, Ron Kalfus, certify that: 1. I have reviewed this Annual Report on Form 20-F of Rosetta Genomics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to |
|
| March 16, 2015 |
As filed with the Securities and Exchange Commission on March 16, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 16, 2015 |
CERTIFICATIONS UNDER SECTION 906 Exhibit 13.1 CERTIFICATIONS UNDER SECTION 906 Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Rosetta Genomics Ltd., an Israeli corporation (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report on Form 20-F for the year ended Dece |
|
| March 16, 2015 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333- 163063, 333-171203, 333-172655, 333-177670 and 333-185338) and Form S-8 (Nos. 333-141525, 333-147805, 333-165722 and 333-191072) pertaining to the Rosetta Genomics Ltd. of our report dated March 16, 2015 with respect to the consoli |
|
| February 18, 2015 |
ROSGF / Rosetta Genomics Ltd. 6-K/A - Current Report of Foreign Issuer - FORM 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2015 (Amendment to report filed February 18, 2015) Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Par |
|
| February 18, 2015 |
ROSGF / Rosetta Genomics Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2015 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| February 18, 2015 |
Up to $14,400,000 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-185338 PROSPECTUS SUPPLEMENT (To Prospectus Dated December 19, 2012) Up to $14,400,000 Ordinary Shares We entered into a Controlled Equity OfferingSM sales agreement, dated February 18, 2015, with Cantor Fitzgerald & Co. relating to our ordinary shares offered by this prospectus supplement and the accompanying prospectus. In accordance with the |
|
| February 18, 2015 |
EXHIBIT 10.1 ROSETTA GENOMICS LTD. Ordinary Shares (par value NIS 0.6 per share) Controlled Equity OfferingSM Sales Agreement February 18, 2015 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Rosetta Genomics Ltd., a corporation formed under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the |
|
| January 12, 2015 |
Rosetta Genomics Issues Letter to Shareholders Exhibit 99.1 News Release Rosetta Genomics Issues Letter to Shareholders PRINCETON, N.J. and REHOVOT, Israel (January 12, 2015) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the posting of the following Letter to Shareholders from President and Chief Executive Officer Kenneth A. Berlin to the Investors section of the Com |
|
| January 12, 2015 |
ROSGF / Rosetta Genomics Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2015 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Exe |
|
| November 12, 2014 |
ROSGF / Rosetta Genomics Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2014 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| November 5, 2014 |
ROSGF / Rosetta Genomics Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2014 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Ex |
|
| October 24, 2014 |
Exhibit 99.2 |
|
| October 24, 2014 |
Exhibit 99.1 October 24, 2014 Dear Rosetta Genomics’ Shareholders: The Rosetta Genomics Board of Directors hereby responds to a Position Paper submitted by Mr. Israel Makov and Mr. Nachum (Homi) Shamir dated October 23, 2014 regarding the Annual General Meeting of Shareholders of Rosetta Genomics to be held November 5, 2014. We welcome open communication with all our shareholders, and we appreciat |
|
| October 24, 2014 |
ROSGF / Rosetta Genomics Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2014 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Exe |
|
| October 15, 2014 |
ROSGF / Rosetta Genomics Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2014 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Exe |
|
| October 15, 2014 |
Exhibit 99.1 ROSETTA GENOMICS LTD. 10 Plaut St., Rabin Science Park Rehovot, 76706 Israel Phone number +972-73-222-0700 SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held On November 5, 2014 Notice is hereby given that an Annual General Meeting (the “Annual Meeting”) of the shareholders of Rosetta Genomics Ltd. (the “Company”), an Israeli corporation, will be held at the offi |
|
| October 14, 2014 |
ROSGF / Rosetta Genomics Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2014 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Exe |
|
| October 1, 2014 |
Exhibit 99.1 ROSETTA GENOMICS LTD. 10 Plaut St., Rabin Science Park Rehovot, 76706 Israel Phone number +972-73-222-0700 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held On November 5, 2014 Notice is hereby given that an Annual General Meeting (the “Annual Meeting”) of the shareholders of Rosetta Genomics Ltd. (the “Company”), an Israeli corporation, will be held at the offices of the Co |
|
| October 1, 2014 |
ROSGF / Rosetta Genomics Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2014 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, Israel (Address of Principal Exe |
|
| September 17, 2014 |
Exhibit 99.2 News Release Rosetta Genomics Reports Financial Results for the First Half of 2014 Demand for microRNA oncology testing services continues its momentum with gross billings growing three-fold, Company executes four research collaborations and advances broad pipeline of microRNA-based assays Business Update Conference Call to be held September 18th at 10:00 a.m. Eastern time PRINCETON, |
|
| September 17, 2014 |
ROSGF / Rosetta Genomics Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 v3887426k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2014 Commission File Number 001-33042 ROSETTA GENOMICS LTD. (Translation of registrant’s name into English) 10 Plaut Street, Science Park Rehovot 76706, I |
|
| September 17, 2014 |
EX-99.1 2 v388742ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ROSETTA GENOMICS LTD. AND ITS SUBSIDIARY CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2014 UNAUDITED INDEX Page Condensed Interim Consolidated Balance Sheets 2 - 3 Condensed Interim Consolidated Statements of Loss 4 Condensed Interim Consolidated Statements of Changes in Shareholders' Equity 5 Condensed Interim Consolidate |
